Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | NEJM
redual - Twitter Search / Twitter
Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI - ScienceDirect
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial - EuroIntervention
REC: Interventional Cardiology - Special article
![AHA2017]RE-DUAL PCI：达比加群双疗治疗亚组分析，获益依旧】-中华医学网-183](http://medline.org.cn/ueditor/jsp/upload/image/20171116/1510827731603053890.png "AHA2017]RE-DUAL PCI：达比加群双疗治疗亚组分析，获益依旧】-中华医学网-183")
AHA2017]RE-DUAL PCI：达比加群双疗治疗亚组分析，获益依旧】-中华医学网-183
Frontiers | Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update | Cardiovascular Medicine
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology
Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation - Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial. | Semantic Scholar
Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement | Business Wire
Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement | Business Wire
PCRonline - The RE-DUAL PCI trial subanalysis: In spite of... | Facebook
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions
Subgroup Analysis from the RE-DUAL PCI Trial | tctmd.com
Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. - Abstract - Europe PMC
REDUAL PCI dual antithrombotic therapy with dabigatran after
Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy | AETOSWire
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | NEJM
on behalf of the RE-DUAL PCI Steering Committee and Investigators - ppt download
PDF) Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in
RE-DUAL PCI Trial: Inclusion and Main Exclusion Criteria and Study Design | ECR Journal
Switching of oral anticoagulation therapy after PCI in patients with atrial fibrillation: The RE-DUAL PCI trial subanalysis
RE-DUAL OAC switching subanalysis animated video | boehringerone.com
Specified subanalysis of the RE-DUAL PCI trial | boehringerone.com
Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug? - European
